- Home
- UTHR vs TOL Comparison
UTHR vs TOL Comparison
Compare UTHR & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- TOL
- Stock Information
- Founded
- UTHR 1996
- TOL 1967
- Country
- UTHR United States
- TOL United States
- Employees
- UTHR N/A
- TOL N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- TOL Homebuilding
- Sector
- UTHR Health Care
- TOL Consumer Discretionary
- Exchange
- UTHR Nasdaq
- TOL Nasdaq
- Market Cap
- UTHR 16.1B
- TOL 14.8B
- IPO Year
- UTHR 1999
- TOL N/A
- Fundamental
- Price
- UTHR $367.97
- TOL $135.58
- Analyst Decision
- UTHR Buy
- TOL Buy
- Analyst Count
- UTHR 14
- TOL 15
- Target Price
- UTHR $378.36
- TOL $153.67
- AVG Volume (30 Days)
- UTHR 280.3K
- TOL 1.5M
- Earning Date
- UTHR 02-19-2025
- TOL 02-18-2025
- Dividend Yield
- UTHR N/A
- TOL 0.68%
- EPS Growth
- UTHR 25.10
- TOL 21.44
- EPS
- UTHR 22.72
- TOL 15.01
- Revenue
- UTHR $2,756,200,000.00
- TOL $10,846,740,000.00
- Revenue This Year
- UTHR $26.19
- TOL $2.34
- Revenue Next Year
- UTHR $10.79
- TOL $7.53
- P/E Ratio
- UTHR $16.19
- TOL $9.03
- Revenue Growth
- UTHR 25.04
- TOL 8.52
- 52 Week Low
- UTHR $208.62
- TOL $95.46
- 52 Week High
- UTHR $417.82
- TOL $169.52
- Technical
- Relative Strength Index (RSI)
- UTHR 53.51
- TOL 54.13
- Support Level
- UTHR $357.25
- TOL $131.81
- Resistance Level
- UTHR $372.34
- TOL $137.51
- Average True Range (ATR)
- UTHR 8.70
- TOL 3.29
- MACD
- UTHR 0.91
- TOL 2.16
- Stochastic Oscillator
- UTHR 79.59
- TOL 80.32
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-home buyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.